Isoniazid
- Generic Name
- Isoniazid
- Brand Names
- Isonarif, Isotamine, Isotamine B, Rifamate, Rifater
- Drug Type
- Small Molecule
- Chemical Formula
- C6H7N3O
- CAS Number
- 54-85-3
- Unique Ingredient Identifier
- V83O1VOZ8L
- Background
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
- Indication
Isoniazid is used for the treatment of all forms of tuberculosis in which organisms are susceptible. It is also used in combination with rifampin and pyrazinamide.
- Associated Conditions
- Active Tuberculosis, Mycobacterium kansasii infection, Late phase Tuberculosis
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- Drug: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)Drug: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)Drug: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Bill & Melinda Gates Medical Research Institute
- Target Recruit Count
- 93
- Registration Number
- NCT05971602
- Locations
- 🇵🇭
Lung Center of the Philippines, Quezon City, Philippines
🇿🇦The Aurum Institute (Tembisa CRS), Johannesburg, South Africa
🇿🇦Perinatal HIV Research Unit (PHRU), Klerksdorp, South Africa
Intensified Short Course Regimen for TBM in Adults
- Conditions
- Tuberculous Meningitis
- Interventions
- Drug: High dose rifampicin (25mg/kg)Drug: HRZEDrug: HREDrug: Steroid
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Indian Council of Medical Research
- Target Recruit Count
- 372
- Registration Number
- NCT05917340
- Locations
- 🇮🇳
ICMR- National Institute for Research in Tuberculosis, Chennai, Tamil Nadu, India
PanACEA - STEP2C -01
- Conditions
- Other Specified Pulmonary TuberculosisPulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Michael Hoelscher
- Target Recruit Count
- 270
- Registration Number
- NCT05807399
- Locations
- 🇲🇼
Kamuzu College of Health Sciences (formerly College of Medicine), Blantyre, Malawi
🇹🇿Kilimanjaro Clinical Research Institute (KCRI), Moshi, Tanzania
🇺🇬Makerere University Lung Institute Limited, Kampala, Uganda
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05592223
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Tuberculosis, PulmonaryHIV
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
- Conditions
- Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- TASK Applied Science
- Target Recruit Count
- 106
- Registration Number
- NCT05473195
- Locations
- 🇿🇦
TASK Clinical Research Centre, Cape Town, Western Cape, South Africa
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
- Conditions
- Tuberculosis InfectionIsoniazid Adverse Reaction
- Interventions
- First Posted Date
- 2022-06-10
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 72
- Registration Number
- NCT05413551
- Locations
- 🇧🇷
Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
- Conditions
- Tuberculous Meningitis
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 330
- Registration Number
- NCT05383742
- Locations
- 🇵🇪
Socios en Salud Sucursal Peru CRS (Site ID: 31985), Lima, Peru
🇵🇪Barranco CRS (Site ID:11301), Lima, Peru
🇵🇭TB HIV Innovations and Clinical Research Foundation Corp (Site ID: 31981), Cavite, Philippines
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.